Clinical trials: Anti-Retroviral Agents
HIV Infections
RHIV A Pilot Study Refractory or Intolerant to Highly Active Antiretroviral Therapy (HAART)
The objectives of this clinical trial are to: Assess the safety of using extracorporeal photoimmune therapy with the photosensitizing agent Uvadex in the treatment of HIV-1 infection; Evaluate the effects of this therapy on HIV-1…
- Trial name
- HIV-HAART (NCT00157027)
- Testing
- Extracorporeal photochemotherapy with UVADEX
- Sponsor
- Atlantic Health System
HIV Infections
A Study to Compare the Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients
The purpose of this study is to examine how the immune systems of HIV-infected patients react to 2 anti-HIV drug combinations.
- Trial name
- NCT00002448
- Testing
- Ritonavir, Efavirenz, Saquinavir
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Hoffmann-La Roche
HIV Infections, HIV-Associated Lipodystrophy Syndrome
MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)
This is a randomized prospective study into metabolic adverse events during different types of initial antiretroviral therapy in HIV-1-infected men.
- Trial name
- NCT00122226
- Testing
- Lopinavir/ritonavir + zidovudine + lamivudine, Lopinavir/ritonavir + nevirapine
- Where
- 13 sites in Finland, Netherlands and 2 more
- Volunteers
- 50 people
- Sponsor
- Amsterdam UMC, location VUmc
Amyotrophic Lateral Sclerosis
HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
Background: Some people with Amyotrophic Lateral Sclerosis (ALS) have a high level of the virus HERV-K in their blood. Researchers do not think this virus causes ALS.
- Trial name
- NCT02437110
- Testing
- Darunavir, Ritonavir, Dolutegravir
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Acquired Immunodeficiency Syndrome
Chinese Network of Pediatric Antiretroviral Therapy
This is an observational cohort in pediatric HIV patients in China. Children who receive antiretroviral drugs will be recruited in this study. The main objectives are as follows: 1.
- Trial name
- CN-PART (NCT01210924)
- Where
- China
- Volunteers
- 400 people
- Sponsor
- National Center for AIDS/STD Control and Prevention, China CDC
Hepatic Steatosis, HIV-1-infection
Adding MAraViroc &/or METformin for Hepatic Steatosis in People Living With HIV
This is a multicentre, phase IV, randomised, open-label, trial exploring adjunctive maraviroc and/or metformin for liver steatosis over 48 weeks.
- Trial name
- MAVMET (NCT03129113)
- Testing
- Maraviroc, Metformin
- Where
- 6 sites in United Kingdom
- Volunteers
- 90 people
- Sponsor
- University College, London
Tuberculosis, Latent Tuberculosis Infection
Isoniazid Plus Antiretroviral Therapy to Prevent Tuberculosis in HIV-infected Persons
The purpose of this study is to evaluate whether isoniazid can safely (and further) reduce the risk of tuberculosis in HIV infected people receiving HAART.
- Conditions
- Tuberculosis, Latent Tuberculosis Infection, HIV Infections
- Trial name
- HAART-IPT (NCT00463086)
- Testing
- isoniazid
- Where
- South Africa
- Volunteers
- 1,368 people
- Sponsor
- University of Cape Town
HIV Infections
ARVs to Prevent Breastmilk HIV:Viral and Immune Responses
Identifying new approaches for preventing breastmilk transmission of HIV-1 is an important research priority. To this end, clinical trials are underway to evaluate the efficacy of HAART (zidovudine, lamivudine, nevirapine) during…
- Trial name
- NCT00167674
- Testing
- Combined short-course zidovudine/nevirapine, HAART
- Where
- Kenya
- Volunteers
- 58 people
- Sponsor
- University of Washington
Anti-Infective Agents, Anti-Retroviral Agents
Safety, PK, and PD Study of IVRs Releasing TFV and LNG
This multi-center Phase I study is designed to characterize the safety, PK, and PD of TFV/LNG IVR to assess systemic and genital tract bioavailability in healthy women.
- Conditions
- Anti-Infective Agents, Anti-Retroviral Agents, Contraceptive Usage
- Trial name
- TFV/LNG IVR (NCT03279120)
- Testing
- TFV/LNG IVR
- Where
- 2 sites in United States, Dominican Republic
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- CONRAD
HIV Infection
Hydroxychloroquine for Discordant CD4 Responders on Highly Active Antiretroviral Therapy (HAART)
The purpose of the study is to examine the effects of adding a drug called hydroxychloroquine, usually used to treat rheumatoid arthritis, to patients' usual antiretroviral combination.
- Trial name
- SSAT039 (NCT01232660)
- Testing
- Hydroxychloroquine
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- St Stephens Aids Trust
HIV-1-infection
MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy
This is a Phase 1, open-label single-center study to determine the safety of MGD014 in participants with human immunodeficiency virus (HIV) infection on stable suppressive antiretroviral therapy (ART).
- Trial name
- NCT03570918
- Testing
- MGD014
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- MacroGenics
Human Immunodeficiency Virus
Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIV
The purpose of this study is to assess the safety and immunogenicity of M72/AS01E vaccination in virally suppressed, antiretroviral-treated participants with human immunodeficiency virus infection (HIV).
- Trial name
- MESA-TB (NCT04556981)
- Testing
- M72/AS01E Mycobacterium tuberculosis vaccine
- Where
- 6 sites in South Africa
- Volunteers
- 402 people
- Sponsor
- Gates Medical Research Institute
Hiv, Adherence, Medication
Making ART Work Among Brazilian Youth
This study seeks to develop and pilot test a theory-based, integrated technology and counseling intervention to improve ART adherence among sexual and gender minority (SGM) young people living with HIV (ages 18-24) in Rio de…
- Trial name
- NCT06056037
- Testing
- Experimental: Making ART Work, Standard of Care
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Brown University
HIV Infections
Optimization of Antiretroviral Therapy
The combination antiretroviral therapy (cART) inhibit HIV replication effectively. However, synergy among these drugs has not been well considered.
- Trial name
- OAT (NCT02935075)
- Testing
- Tenofovir disoproxil fumarate, Lamivudine, Efavirenz
- Where
- 3 sites in China
- Volunteers
- 184 people
- Sponsor
- Shanghai Public Health Clinical Center
Opioid-use Disorder, HIV-1-infection
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
HIV infection, as well as exposure to opioids (including heroin), are associated with systemic immune activation including increased microbial translocation from the gut.
- Conditions
- Opioid-use Disorder, HIV-1-infection, Immune Activation, Inflammation
- Trial name
- AMOHI-1 (NCT04480554)
- Testing
- Methadone, Buprenorphine/naloxone, XR-Naltrexone
- Where
- 2 sites in United States, Vietnam
- Volunteers
- 78 people
- Sponsor
- University of Pennsylvania
HIV
Integrating U=U Into HIV Counseling in South Africa
The near-elimination of HIV transmission with antiretroviral therapy (ART) has provided the world with a clear path to end the HIV epidemic through the mass provision of ART at diagnosis, i.e. test-and-treat.
- Trial name
- INTUIT-SA (NCT04504357)
- Testing
- Tablet based U=U app, Text messages
- Where
- 3 sites in South Africa
- Volunteers
- 135 people
- Sponsor
- Boston University
HIV
Strategic Antiretroviral Therapy and HIV Testing for Youth in Rural Africa
The goal of this study is to evaluate the effect of a combination intervention on long-term HIV viral load (VL) suppression among HIV-infected adolescents and young adults 15-24 years of age.
- Trial name
- NCT03848728
- Testing
- SEARCH Youth combination intervention
- Where
- 2 sites in Kenya, Uganda
- Volunteers
- 1,988 people
- Sponsor
- University of California, San Francisco
Human Immunodeficiency Virus
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
The primary purpose of this study is to determine the pharmacokinetic properties (what the body does to maraviroc) and to determine a suitable dosing schedule of maraviroc in HIV-1 infected children and adolescents.
- Trial name
- NCT00791700
- Testing
- Maraviroc
- Where
- 41 sites in United States, Brazil and 7 more
- Volunteers
- 103 people
- Sponsor
- ViiV Healthcare
HIV Infections
Vedolizumab Treatment in HIV-Infected Subjects Without Previous Antiretroviral Therapy
HIV cannot be eliminated and remains in the body despite the treatment that is used for HIV-infection called antiretroviral treatment (ART). Individuals undergoing ART interruption rapidly experience virus rebound in the blood.
- Trial name
- NCT03577782
- Testing
- Entyvio (Vedolizumab)
- Where
- Spain
- Volunteers
- 12 people
- Sponsor
- Hospitales Universitarios Virgen del Rocío
HIV Infection
TMC125-C211: Trial of TMC125 in HIV-1 Infected Subjects Who Were in a Sponsor Selected TMC125 Trial
This is a Phase II, open-label, roll-over trial to evaluate the long term safety and tolerability of TMC125, administered as part of an individually optimized antiretroviral therapy, in HIV 1 infected subjects.
- Trial name
- NCT00111280
- Testing
- TMC125
- Volunteers
- 48 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.